Allucent is focused on helping small and mid-size biotech sponsors navigate the clinical trial process from strategy to approval, aiming to bring your breakthrough ideas to patients awaiting them. With more than 30 years of worldwide experience in trial design and execution, complex therapeutic areas, and challenging indications, we are ready to join you as a valuable partner and trusted extension of your team’s capabilities.
Building relationships with your partners – physicians, investigators, hospital personnel – is fundamental to the effective conduct of your clinical trials. This is the primary responsibility of the clinical research associate (CRA), who works on the front lines of your study as protocol and project manager.
Highly experienced personnel are essential for this role, as they are responsible for key elements of clinical operations. This encompasses regulatory approval to commence the trial, site selection, training on study protocol, and supporting and overseeing site performance and safety throughout the project. The CRA oversees patient recruitment, compliance with patient profile and protocol, and quality-driven assessment to ensure that the expectations of both the sponsor and regulators are met.
Allucent CRAs work side by side with your team, lending deep knowledge gained through extensive collaboration with small and mid-sized biotech companies on countless projects. Our CRA team comprises the A-team: physicians and PhD scientists extending across the EU, including Eastern Europe, North America, and Latin America, with an additional hub covering India and Africa. Our global footprint enables us to support you through later phases, and to observe regional differences, detect trends across multiple sites, and take proactive steps to mitigate potential risks in data quality.
Each trial benefits from a CRA with experience in the relevant therapeutic area. The CRA understands the practicalities of executing the study in the clinic as well as the challenges of the project team and sponsor – a perspective that supports pragmatic protocol design. Our flexible, adaptable approach is especially important for small and mid-size biotechs that occasionally encounter business adjustments or changing priorities during the course of the study.